Lipocine Inc

Research Lipocine Inc (LPCN) on Bullrun: market cap USD 17.73M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 17.73M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 1.98M-USD 9.63M-USD 9.76Mn/a-1.69USD 5.21Mn/aUSD 14.48M
FY2024USD 11.20MUSD 10.00K-USD 1.31Mn/a-0.35USD 6.21Mn/aUSD 21.00M
FY2023-USD 2.85M-USD 16.35M-USD 11.88Mn/a-3.14USD 4.77Mn/aUSD 20.37M
FY2022USD 500.00K-USD 10.76M-USD 12.10Mn/a-2.15USD 3.15MUSD 2.32MUSD 35.63M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 17.73Mn/an/an/a
20252025-12-31USD 49.45Mn/an/an/a
20242024-12-31USD 26.10M488.0n/an/a
20232023-12-29USD 14.83Mn/an/an/a
20222022-12-30USD 35.25M8.6n/an/a
20212021-12-31USD 87.51Mn/an/an/a

About Lipocine Inc

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Lipocine Inc's market cap?

Lipocine Inc's market capitalization is USD 17.73M.

What does Lipocine Inc do?

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.